Appendix A: Clinical Decision Aid for Use of Progesterone to Prevent Preterm Birth

**Progesterone to prevent preterm birth: Screening and treatment workflow**

**Pregnant member with singleton gestation**

**Prior preterm delivery**

- **No**
  - Transvaginal ultrasonography: cervical length assessment (once between 16-24 weeks)
  - Gestational age: 16-24 weeks

- **Yes**
  - Prior preterm delivery: singleton
  - **No**
    - Cervical length monitoring every 2 weeks until 24 weeks of gestation (transvaginal ultrasound)
    - Cervical length monitoring every week until 24 weeks of gestation (transvaginal ultrasound)
  - Prior preterm delivery: medically-indicated
  - **Yes**
    - Transvaginal ultrasonography: cervical length assessment (once between 16-24 weeks)
    - Cervical length monitoring every week until 24 weeks of gestation (transvaginal ultrasound)

**Case Manager Interaction**

**Initiate intramuscular 17P (250 mg weekly until 36 weeks)**

**Multiple gestation: progesterone not indicated; expectant management**

**Gestational age: At least 16 weeks**

- **> 30mm**
  - Transvaginal ultrasonography: cervical length assessment
  - Cervical length monitoring every 2 weeks until 24 weeks of gestation (transvaginal ultrasound)
  - Cervical length monitoring every week until 24 weeks of gestation (transvaginal ultrasound)

- **25-30 mm**
  - Transvaginal ultrasonography: cervical length assessment
  - Cervical length monitoring every 2 weeks until 24 weeks of gestation (transvaginal ultrasound)
  - Cervical length monitoring every week until 24 weeks of gestation (transvaginal ultrasound)

- **< 25 mm**
  - Evaluation for cerclage placement
  - Transvaginal ultrasonography: cervical length assessment
  - Cervical length monitoring every 2 weeks until 24 weeks of gestation (transvaginal ultrasound)
  - Cervical length monitoring every week until 24 weeks of gestation (transvaginal ultrasound)

**Non-spontaneous prior preterm delivery: progesterone not indicated; expectant management**

- **< 20mm**
  - Nightly vaginal progesterone until 36 weeks of gestation (90 mg gel or 200 mg capsule)

**Archived Document:** This report does not reflect the current evidence. While it may be used for historical and research purposes, it should not be used to guide clinical or policy decisions.